Trial Profile

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melatonin/tetrahydrocannabinol (Primary) ; Melatonin/tetrahydrocannabinol (Primary)
Indications Alzheimer's disease; Dementia
Focus Therapeutic Use
Acronyms CALMA; IGC-AD1-P2
Sponsors India Globalization Capital

25 Nov 2024 Interim results published in the IGC Pharma Media Release
16 Apr 2024 Interim Results demonstrating a clinically significant reduction, approaching statistical significance, in agitation in Alzheimers at week two compared to placebo, published in the IGC Pharma Inc. media release.
09 Apr 2024 According to an IGC Pharma Inc. media release, Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma's lead therapeutic candidate targeting agitation in Alzheimer's disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com